42Stockpicking

BLFS

Biolife Solutions IncKøb· 71.2%· 20. jun. 2026
NASDAQ·Healthcare·USD

Henter pris…

Værdiansættelse (TTM)

P/Ei
EV/EBITDAi
P/Bi
3,3
54th %ile · 64p
P/Si
195,5
98th %ile · 70p
EV/Salesi
192,6
98th %ile · 70p
Div yieldi

Kursudvikling

Pris

Data-readiness

10 års prishistorik er idealet for høj confidence.

Beregnet 24.6.2026strong
Prishistorik
30,1 år
Pris-dage
7585
Årsregnskaber
17
Peers
0/0
Valuation
3/6
Fundamentals
8/8
Datovindue
1996-04-30 til 2026-06-23

Blokkere

  • Raw confidence is below the 0.95 high-confidence guardrail.

Mangler før højere confidence

  • Kør compute-multiples for manglende valuation metrics.

Seneste assessment

BLFS vurderet 2026-06-24

Score
43.5%
Ikke high-confidence

Raw confidence is below the 0.95 high-confidence guardrail.

Sell watch placeholder

Stores exit-aware fields without issuing sell scores yet.

24%

Current drawdown: Future exit logic can use drawdown from recent high.

Trend break: Future exit logic can use moving-average trend breaks.

Valuation

Compares price paid with earnings, cash-generation proxies and sales.

34%

P/E: Reasonable P/E gets rewarded; very expensive or distressed multiples do not.

Earnings yield: Earnings yield is the inverse P/E lens.

Technicals

Checks trend, momentum and current damage from recent highs.

38%

6M momentum: Positive medium-term momentum confirms sponsorship.

Trend stack: Strong setup keeps price above MA50 and MA200 with MA50 above MA200.

Data quality

Checks whether the assessment has enough recent price, fundamental and valuation data.

71%

Price history depth: More than one trading year gives the technical pillar enough context.

Latest price freshness: Latest live or EOD price should be recent.

Macro/regime

Treats macro as context, not a standalone trading instruction.

47%

VIX: Normal volatility is supportive; panic or complacency is less clean.

10Y-2Y curve: Positive yield curve lowers recession stress.

Fundamentals

Scores growth, margins, capital efficiency, balance-sheet resilience and composite financial-health KPIs.

68%

Revenue growth 3Y: Sustained top-line growth supports durable compounding.

Gross margin: High gross margin gives room for reinvestment and downturns.

Peer/relative context

Adds relative context when sector peers have comparable data.

48%

Peer count: Peer context is only scored when comparable data exists.

P/E vs peers: P/E relative valuation needs both own multiple and peer median.

Insider activity

Net 90d (aktier)
-1.200.000
Net 90d (værdi)
-28.125.000 USD
Købere 90d
0
Cluster
DatoPersonRolleTypeAntalVærdiKilde
18.6.2026DE GREEF RODERICKPresident and CEO· ANDET-2.775-72.261 USDsec
18.6.2026Mathew Aby J.EVP & Chief Scientific Officer· ANDET-564-14.687 USDsec
18.6.2026Wichterman TroyChief Financial Officer· ANDET-937-24.399 USDsec
18.6.2026Berard ToddChief Marketing Officer· ANDET-470-12.239 USDsec
18.6.2026Werner SeanChief Technology Officer· ANDET-420-10.937 USDsec
8.6.2026Wichterman TroyChief Financial Officer· ANDET-1.026-26.779 USDsec
8.6.2026Mathew Aby J.EVP & Chief Scientific Officer· ANDET-627-16.365 USDsec
8.6.2026Berard ToddChief Marketing Officer· ANDET-356-9.292 USDsec
21.5.2026▼ SALG-650.000-15.405.000 USDsec
20.5.2026▼ SALG-250.000-5.925.000 USDsec
19.5.2026▼ SALG-300.000-6.795.000 USDsec

Earnings

QuarterDateEPS actualEPS estEPS surpriseRevenue surprise
2026Q130.4.20260,040,02+160.9%+160.9%Beat
2025Q430.1.20260,040,01+680.0%+680.0%Beat
2025Q330.10.20250,040,00+1997.5%+1997.5%Beat
2025Q230.7.20250,01-0,01+220.0%+220.0%Beat